F. Naguib

发表

Uptake of Nitrobenzylthioinosine and Purine β-l-Nucleosides by Intracellular Toxoplasma gondii

O. N. Al Safarjalani, F. Naguib, M. H. El Kouni, 2003, Antimicrobial Agents and Chemotherapy.

Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.

C. K. Chu, Ashoke Sharon, Young Ah Kim, 2007, Biochemical pharmacology.

Metabolism and Selective Toxicity of 6-Nitrobenzylthioinosine in Toxoplasma gondii

V. Guarcello, O. N. Al Safarjalani, F. Naguib, 1999, Antimicrobial Agents and Chemotherapy.

Insertional tagging of at least two loci associated with resistance to adenine arabinoside in Toxoplasma gondii, and cloning of the adenosine kinase locus.

D. Roos, C. Wilson, W. Sullivan, 1999, Molecular and biochemical parasitology.

6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es).

J. Buolamwini, C. K. Chu, V. Yadav, 2005, Biochemical pharmacology.

7-Deaza-6-benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities.

C. K. Chu, Y. A. Kim, O. N. Al Safarjalani, 2005, Biochemical pharmacology.

Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines.

F. Naguib, M. H. el Kouni, M. E. el Kouni, 1993, Cancer research.

Two Drosophila melanogaster mutations block successive steps of de novo purine synthesis.

S. Henikoff, D. Patterson, J. Woolford, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Kinetic mechanism of Toxoplasma gondii adenosine kinase and the highly efficient utilization of adenosine.

O. N. Al Safarjalani, F. Naguib, R. Rais, 2015, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

Nucleoside kinases in adult Schistosoma mansoni: phosphorylation of pyrimidine nucleosides.

F. Naguib, M. H. el Kouni, Fardos N M Naguib, 2014, Molecular and biochemical parasitology.

Pyrimidine salvage pathways in adult Schistosoma mansoni.

F. Naguib, M. H. el Kouni, 1990, International journal for parasitology.

Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.

P. Calabresi, S. Chu, S. Cha, 1984, Cancer research.

Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.

F. Naguib, M. H. el Kouni, S. Hao, 1994, Cancer research.

Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy.

R. Diasio, S. Soong, R. Zhang, 1991, Biochemical pharmacology.

Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines.

S. Soong, F. Naguib, M. H. el Kouni, 1993, Biochemical pharmacology.

Effects of N,N-dimethylformamide and sodium butyrate on enzymes of pyrimidine metabolism in cultured human tumor cells.

M. Wiemann, S. Cha, F. Naguib, 1987, Leukemia research.

Phenylselenenyl- and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase.

R. Schinazi, F. Naguib, M. H. el Kouni, 1993, Journal of medicinal chemistry.

Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver.

S. Cha, F. Naguib, M. H. el Kouni, 1989, Biochemical pharmacology.

Uridine phosphorylase inhibitors: chemical modification of benzyloxybenzyl-barbituric acid and its effects on urdpase inhibition.

O. N. Al Safarjalani, F. Naguib, R. P. Panzica, 1999, Bioorganic & medicinal chemistry letters.

Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.

O. Ashour, F. Naguib, R. P. Panzica, 1995, Cancer research.

Synthesis of a new class of uridine phosphorylase inhibitors

C. Tzeng, E. Wang, F. Naguib, 1993 .

Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii.

R. Schinazi, C. K. Chu, S. Chu, 1996, Biochemical pharmacology.

5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase.

E. Wang, F. Naguib, R. P. Panzica, 1993, Biochemical pharmacology.

New analogues of benzylacyclouridines, specific and potent inhibitors of uridine phosphorylase from human and mouse livers.

S. Chu, S. Cha, F. Naguib, 1987, Biochemical pharmacology.

Three purine auxotrophic loci on the second chromosome of Drosophila melanogaster

F. Naguib, D. Nash, M. E. Johnstone, 1985, Biochemical Genetics.

Tight binding inhibitors--IX. Kinetic parameters of dihydrofolate reductase inhibited by methotrexate, an example of equilibrium study.

P. Kantoff, S. Kornstein, S. Cha, 1981, Biochemical pharmacology.

Synthesis of [4-(hydroxy)tetrahydrofuran-2-yl]nucleosides as a novel class of uridine phosphorylase inhibitors

L. Kotra, C. K. Chu, Q. Teng, 1995 .

5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens

R. Schinazi, Junxing Shi, O. N. Al Safarjalani, 2005, Cancer Chemotherapy and Pharmacology.

Differences Â¡nActivities and Substrate Specificity of Human and Murine Pyrimidine Nucleoside Phosphorylases: Implications for Chemotherapy with 5-Fluoropy

Mahmoud, F. Naguib, M. E. Kouni, 2006 .

Enzymes of uracil catabolism in normal and neoplastic human tissues.

F N Naguib, M H el Kouni, S Cha, 1985, Cancer research.

Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.

C. K. Chu, Jakyung Yoo, Ashoke Sharon, 2010, Bioorganic & medicinal chemistry.

Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.

C. K. Chu, Ashoke Sharon, Y. A. Kim, 2008, Journal of medicinal chemistry.

Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.

C. K. Chu, V. Yadav, V. Guarcello, 2004, Journal of medicinal chemistry.

Effect of the N-glycosidic bond conformation and modifications in the pentose moiety on the binding of nucleoside ligands to uridine phosphorylase.

J. Imbach, S. Chu, S. Cha, 1988, Molecular pharmacology.

O5′,6-Methanocytidine — Synthesis, Conformational Properties and Deamination by Cytidine Deaminase

S. Ealick, R. Klein, F. Naguib, 1994 .

5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase.

R. Schinazi, O. N. Al Safarjalani, F. Naguib, 2000, Biochemical pharmacology.

Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice.

S. Soong, K. Park, S. Cha, 1990, Biochemical pharmacology.

Synthesis And Biological Activity Op Hydpdxymetflyl Analogs op 5-Benzylacyclouridine and 5-Benzyloxybenzylacycloaridine

S. Chu, F. Naguib, M. Chu, 1984 .

Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity

O. N. Al Safarjalani, F. Naguib, R. Rais, 2012, Cancer Chemotherapy and Pharmacology.

Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor

R. Schinazi, Junxing Shi, O. N. Al Safarjalani, 2006, Cancer Chemotherapy and Pharmacology.

Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.

O. Ashour, O. N. Al Safarjalani, F. Naguib, 2000, Biochemical pharmacology.

Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy

R. Schinazi, O. Ashour, O. N. Al Safarjalani, 2000, Cancer Chemotherapy and Pharmacology.

5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy.

O. Ashour, F. Naguib, M. H. el Kouni, 1996, Biochemical pharmacology.

Uridine phosphorylase from Schistosoma mansoni.

S. Cha, F. Naguib, J. G. Niedzwicki, 1988, The Journal of biological chemistry.

Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.

R. Schinazi, O. Ashour, F. Naguib, 2000, Biochemical pharmacology.

Synthesis of 5-Benzyl and 5-Benzyloxybenzyl 2,2′-Anhydrouridines and Related Nucleoside Analogs as Inhibitors of Uridine Phosphorylase

E. Chu, S. Chu, S. Cha, 1988 .

AS Triazine Acyclonucleosides: Potential Inhibitors of Pyrimidine Enzymes1

S. Purkayastha, F. Naguib, R. P. Panzica, 1989 .

Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy

R. Schinazi, Junxing Shi, F. Naguib, 2001, Cancer Chemotherapy and Pharmacology.

Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy

R. Schinazi, O. N. Al Safarjalani, F. Naguib, 2001, Cancer Chemotherapy and Pharmacology.

Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy

R. Schinazi, O. Ashour, F. Naguib, 2000, Cancer Chemotherapy and Pharmacology.

cently synthesized as a potent and specific inhibitor of uridine phospho

O. Ashour, F. Naguib, R. P. Panzica, 2006 .

Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity

C. Blanquicett, V. Guarcello, F. Naguib, 2008, Cancer Chemotherapy and Pharmacology.

Enzymes of pyrimidine salvage pathways in intraerythrocytic Plasmodium falciparum.

Craig M. Wilson, F. Naguib, M. H. el Kouni, 2018, The international journal of biochemistry & cell biology.

Nucleoside auxotrophy in Drosophila: An autosomal locus yielding mutants supplementable by purine and pyrimidine ribonucleosides

F. Naguib, D. Nash, 1976, Molecular and General Genetics MGG.

The Adenosine Transporter of Toxoplasma gondii

D. Roos, N. Carter, R. Donald, 1999, The Journal of Biological Chemistry.

Carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase: biological activities and selective toxicities.

C. K. Chu, Y. A. Kim, O. N. Al Safarjalani, 2010, Biochemical pharmacology.

Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.

R. Zhang, Q. Cai, F. Naguib, 1997, International journal of oncology.

A genetic and dietary study of the physiology of pyrimidine synthesis in Drosophila melanogaster

F. Naguib, M. E. Kouni, D. Falk, 1980 .

SYNTHESIS OF CARBOCYCLIC OROTIDINE ANALOGS AS POTENTIAL OROTIDINE DECARBOXYLASE INHIBITORS

C. K. Chu, F. Naguib, G. Song, 2001, Nucleosides, nucleotides & nucleic acids.

Isolation and characterization of deficiencies exposing the rudimentary locus of Drosophila melanogaster.

B. Jarry, F. Naguib, 1981, Genetical research.

Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii.

F. Naguib, R. P. Panzica, M. H. Kouni, 1995, Biochemical pharmacology.